公开(公告)号：US20230241101A1

公开(公告)日：2023-08-03

申请号：US17927390

申请日：2021-05-20

申请人： BEIJING BJUT SCIENCE AND TECHNOLOGY PARK CO., LTD

发明人： Xueyun GAO

IPC分类号： A61K33/242 ,  A61K31/80 ,  A61P31/14 ,  A61K47/64 ,  A61K31/7135

CPC分类号： A61K33/242 ,  A61K31/80 ,  A61K31/7135 ,  A61K47/645 ,  A61P31/14

摘要： Provided is a therapeutic composition for treatment of coronavirus infection. The therapeutic composition contains a gold compound that generates Au—S bonds at the active pockets of the main protease of the virus while suppressing the virus-induced inflammations in the body.

公开(公告)号：US20230201246A1

公开(公告)日：2023-06-29

申请号：US17997493

申请日：2021-04-29

申请人： THE UNIVERSITY OF MASSACHUSETTS

发明人： Mingdi YAN ,  William NDUGIRE ,  Olof RAMSTROM ,  N.G. Hasitha RAVIRANGA

IPC分类号： A61K31/7135 ,  A61K33/242 ,  A61K45/06 ,  A61K47/20 ,  A61P31/04

CPC分类号： A61K31/7135 ,  A61K33/242 ,  A61K45/06 ,  A61K47/20 ,  A61P31/04

摘要： Compositions comprising metal entities in combination with an activating agent, or pharmaceutically acceptable salts thereof are disclosed. Certain compositions are active as antibacterial, antiviral, antifungal, anti-protozoal, and/or anti-worm agents. The disclosure provides pharmaceutical compositions containing the compositions. Methods of using the composition to treat bacterial infections are disclosed.

公开(公告)号：US20230131943A1

公开(公告)日：2023-04-27

申请号：US17914301

申请日：2021-03-23

申请人： Micheal W. Burnet

发明人： Michael W. Burnet

IPC分类号： A61K31/7052 ,  A61K31/4706 ,  A61P31/04 ,  A61K31/222 ,  A61K31/138 ,  A61K31/4439 ,  A61K31/415 ,  A61K31/7135 ,  A61K33/30 ,  A61K31/133 ,  A61K31/5377 ,  A61K31/24 ,  A61P31/14

摘要： Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease and are immune stimulatory, promote zinc uptake, disable endosomal reactions and synergise anti-viral action of protease inhibitors. The compounds are useful for the treatment of bacterial, viral and mixed pneumonias.

公开(公告)号：US20220193109A1

公开(公告)日：2022-06-23

申请号：US17604864

申请日：2020-04-23

申请人： MEMORIAL SLOAN KETTERING CANCER CENTER ,  ALGEN BIOTECHNOLOGIES, INC.

发明人： Chun-Hao HUANG ,  Spencer Charles KNIGHT ,  Scott LOWE

IPC分类号： A61K31/7088 ,  A61P35/00 ,  A61K31/7068 ,  G01N33/50 ,  A61K31/519 ,  C12N15/113 ,  A61K31/7135 ,  A61K31/4412

摘要： The present disclosure relates generally to compositions and methods for the treatment of a RAS-mutant cancer. In particular, the present technology relates to administering a therapeutically effective amount of one or more TXNRD1 inhibitors to a subject diagnosed with, or at risk for a RAS-mutant cancer (e.g., RAS-mutant pancreatic cancer).

公开(公告)号：US20210369770A1

公开(公告)日：2021-12-02

申请号：US17181597

申请日：2021-02-22

申请人： Xueyun Gao

发明人： Xueyun Gao

IPC分类号： A61K33/242 ,  A61K31/80 ,  A61K31/7135 ,  A61K47/64 ,  A61P31/14

摘要： A therapeutic composition for treatment of coronavirus infections. The therapeutic composition contains a gold compound effective for Rheumatoid Arthritis treatment that both generates gold-S bonds at the active pockets of the main protease of the virus and suppresses the virus induced inflammations in the body.

公开(公告)号：US20200338157A1

公开(公告)日：2020-10-29

申请号：US16921610

申请日：2020-07-06

申请人： THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE ,  ARIZONA BOARD OF REGENTS ON BEHALF OF NORTHERN ARIZONA UNIVERSITY

发明人： David Engelthaler ,  Elizabeth Driebe ,  Hongwei "Holly" Yin ,  Michael Valentine ,  Donald Chow ,  Jolene Bowers ,  Paul Keim ,  Bridget Barker

IPC分类号： A61K38/13 ,  A61K31/7135 ,  A61K31/58 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/4196 ,  A61K31/496 ,  A61K31/495 ,  A61K45/06 ,  A61K31/138 ,  A61K31/277 ,  A61K31/353 ,  A61K31/404 ,  A61K31/4174 ,  A61K31/428 ,  A61K31/4741 ,  A61K31/609

摘要： The present invention comprises methods of treating an infection using a pharmaceutical composition comprising an active ingredient selected from Table 1. In some aspects, the infection can be caused by one or more pathogens, including fungal pathogens. For example, the infection may b

公开(公告)号：US20200317714A1

公开(公告)日：2020-10-08

申请号：US16843567

申请日：2020-04-08

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Adam R. Renslo ,  Erica M.W. Lauterwasser ,  Shaun D. Fontaine ,  Benjamin B. Spangler ,  James A. Wells

IPC分类号： C07H19/16 ,  C07F7/18 ,  C07D407/12 ,  C07D405/14 ,  C07D323/02 ,  C07D405/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/14 ,  C07D493/04 ,  C07D519/04 ,  C07F9/655 ,  C07H19/06 ,  C07H19/167 ,  A61K47/64 ,  A61K47/68 ,  C07F9/6558 ,  A61K31/357 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/4192 ,  A61K31/427 ,  A61K31/435 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/513 ,  A61K31/662 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/7135 ,  A61K51/04 ,  C07D487/04 ,  C07D491/107 ,  C07D491/113 ,  C07D491/153 ,  C07D493/14 ,  C07K7/06

摘要： Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a phannaceutically acceptable carrier.

公开(公告)号：US10716802B2

公开(公告)日：2020-07-21

申请号：US14776594

申请日：2014-03-13

申请人： The Brigham and Womens Hospital, Inc.

发明人： Jeffrey M. Karp ,  Yuhan Lee ,  Ali Tavakkoli ,  Tarawatie E. Deelman

IPC分类号： A61K31/7135 ,  A61K9/16 ,  A61K9/50 ,  A61K33/20 ,  A61K33/38 ,  A61K33/18 ,  A61K9/48

摘要： This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.

公开(公告)号：US20190284224A1

公开(公告)日：2019-09-19

申请号：US16364577

申请日：2019-03-26

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Adam R. Renslo ,  Erica M.W. Lauterwasser ,  Shaun D. Fontaine ,  Benjamin B. Spangler ,  James A. Wells

IPC分类号： C07H19/16 ,  C07F7/18 ,  C07D407/12 ,  A61K47/64 ,  A61K47/68 ,  C07F9/655 ,  A61K31/4025 ,  C07D493/14 ,  C07D491/153 ,  C07D491/113 ,  C07D491/107 ,  C07D487/04 ,  A61K51/04 ,  A61K31/7135 ,  A61K31/7076 ,  A61K31/7072 ,  A61K31/662 ,  A61K31/513 ,  A61K31/4985 ,  A61K31/496 ,  A61K31/4745 ,  A61K31/4709 ,  A61K31/444 ,  A61K31/437 ,  A61K31/435 ,  A61K31/427 ,  A61K31/4192 ,  A61K31/404 ,  C07K7/06 ,  A61K31/357 ,  C07H19/167 ,  C07H19/06 ,  C07D519/04 ,  C07D493/04 ,  C07D471/14 ,  C07D417/14 ,  C07D417/12 ,  C07D405/12 ,  C07D323/02 ,  C07D405/14

摘要： Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5]decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.

公开(公告)号：US20190125769A1

公开(公告)日：2019-05-02

申请号：US16092742

申请日：2017-04-10

申请人： Yeda Research and Development Co. Ltd. ,  Memorial Sloan-Kettering Cancer Center

发明人： Avigdor SCHERZ ,  Yoram SALOMON ,  LiIach AGEMY ,  Rachel HAMRI ,  Dina PREISE ,  Kwanghee KIM ,  Jonathan COLEMAN

IPC分类号： A61K31/675 ,  A61K31/409 ,  A61K31/7068 ,  A61K31/7135 ,  A61P35/00

摘要： An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter “Bchl-D) for use in combination therapy for cancer, wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).